Mankind Pharma Ltd. benchmarking: Performance to industry peers

Financial

	Mankind Pharma	Zydus Lifesciences	Aurobindo Pharma
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	67.0 .	505.0 .	879.0 .
Number of ANDA's Approved By USFDA	48.0 .	428.0 .	750.0 .
Domestic Sales Growth - YoY	8.4 %	12.7 %	n/a
R&D as a % of Total Sales	2.2 %	8.8 %	4.7 %
Unclassified
Advertisement Spend as a % of Total Sales	6.19 %	n/a	n/a
Financials
5 yr Average ROE	20.33 %	18.47 %	12.72 %
5yr average Equity Multiplier	1.46	1.52	1.46
5yr Average Asset Turnover Ratio	0.81	0.66	0.68
5yr Avg Net Profit Margin	17.68 %	19.02 %	12.5 %
Price to Book	5.39	3.44	2.21
P/E	46.34	17.61	22.25
5yr Avg Cash Conversion Cycle	-13.08 Days	-84.89 Days	-46.37 Days
Inventory Days	59.06 Days	36.38 Days	59.62 Days
Days Receivable	34.35 Days	36.93 Days	30.33 Days
Days Payable	121.69 Days	160.15 Days	121.28 Days
5yr Average Interest Coverage Ratio	46.07	30.19	43.54
5yr Avg ROCE	25.06 %	19.65 %	15.27 %
5yr Avg Operating Profit Margin	24.62 %	24.4 %	19.22 %
5 yr average Debt to Equity	0.16	0.17	0.19
5yr CAGR Net Profit	9.49 %	16.23 %	-8.16 %
5yr Average Return on Assets	14.46 %	12.22 %	8.64 %
Shareholdings
Promoter Holding	72.66 %	75.0 %	51.82 %
Share Pledged by Promoters	0.0	0.0	17.5 %
Change in Promoter Holding (3 Yrs)	-3.84 %	0.02 %	-0.01 %
Change in Mutual Fund Holding (3 Yrs)	7.47 %	-0.85 %	12.02 %

Business

	Mankind Pharma	Zydus Lifesciences	Aurobindo Pharma
Product Wise Break-Up	Product Wise Break-Up Cardiovascular 16.0 Anti-infectives 13.0 Gynaecology 10.0 Anti-Diabetic 9.0 Respiratory 9.0 Gastrointestinal 9.0 VMN 8.0 Urology 5.0 Dermatology 5.0 Pain/Analgesics 4.0 Neuro/CNS 2.0 IM Formulations 0 Emerging Markets 0 Europe Formulatios 0 Alliances 0 API 0 Wellness 0 Animal Health 0 India Formulations 0 US Formulations 0 Formulations 0 Others 10.0	Product Wise Break-Up Alliance 0.1 Cardiovascular 0 Active Pharmaceutical Ingredient (API) 3.0 Gastrointestinal 0 Urology 0 Europe Formulatios 0 VMN 0 Animal Health 0 Wellness 14.0 Neuro/CNS 0 Respiratory 0 Formulations 0 US Formulations 41.0 EMB Formulations 12.0 India Formulations 25.0 Gynaecology 0 Anti-infectives 0 Emerging Markets 0 Pain/Analgesics 0 Dermatology 0 Anti-Diabetic 0 Others 4.9	Product Wise Break-Up Alliances 0 Cardiovascular 0 Active Pharmaceutical Ingredient (API) 11.14 Gastrointestinal 0 Urology 0 Europe Formulatios 0 VMN 0 Animal Health 0 Wellness 0 Neuro/CNS 0 Respiratory 0 Formulations 88.86 US Formulations 0 IM Formulations 0 India Formulations 0 Gynaecology 0 Anti-infectives 0 Emerging Markets 0 Pain/Analgesics 0 Dermatology 0 Anti-Diabetic 0
Location Wise Break-Up	Location Wise Break-Up India 85.0 Nepal 0 Sri Lanka 0 Bangladesh 0 USA 0 Europe 0 Rest of the World 0 Others 15.0	Location Wise Break-Up India 39.81 Bangladesh 0 Sri Lanka 0 Rest of the World 0 Europe 0 USA 47.94 Nepal 0 Others 12.25	Location Wise Break-Up India 9.0 Bangladesh 0 Sri Lanka 0 Rest of the World 16.5 Europe 31.3 USA 43.2 Nepal 0
Location Wise Break-Up	Location Wise Break-Up India 85.0 Nepal 0 Sri Lanka 0 Bangladesh 0 USA 0 Europe 0 Rest of the World 0 Others 15.0	Location Wise Break-Up India 39.81 Bangladesh 0 Sri Lanka 0 Rest of the World 0 Europe 0 USA 47.94 Nepal 0 Others 12.25	Location Wise Break-Up India 9.0 Bangladesh 0 Sri Lanka 0 Rest of the World 16.5 Europe 31.3 USA 43.2 Nepal 0
Acute vs Chronic	Acute vs Chronic Acute 60.7 Chronic 39.3	-	-
Brand Wise Break-Up	Brand Wise Break-Up Manforce (Rx) 13.29 Telmikind 11.68 Moxikind 9.63 Amlokind 6.74 Unwanted 6.12 Prega News 5.66 Dydroboon 5.48 Candiforce 4.89 Glimestar 4.84 Cefakind 3.36 Gudcef 3.04 Monticope 2.89 Asthakind 2.69 Zenflox 0 Mahacef 0 Codistar 0 Nurokind 0 Others 19.69	-	-

Mankind Pharma Ltd.

Mankind Pharma Ltd.

Financial

Business

SIGN UP FOR FREE